E. Falcó

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer

Julieta Grasselli, Elena Élez, Ginevra Caratù et al. · Annals of Oncology · 2017 · 194 citations · Full text

Medicine, Molecular Medicine, Oncology +17

First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

Enrique Aranda, Pilar García‐Alfonso, Manuel Benavides et al. · European Journal of Cancer · 2018 · 82 citations

Medicine, Oncology, Pharmacotherapy +16

Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial

Fernando Rivera, Marta Izquierdo-Manuel, Pilar García‐Alfonso et al. · European Journal of Cancer · 2021 · 65 citations

Medicine, Oncology, Surgery +17

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial

Cristina Santos, Daniel Azuara, J.M. Viéitez et al. · Annals of Oncology · 2019 · 29 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti–Epidermal Growth Factor Receptor Therapy

Joan Maurel, Vicente Alonso, P. Escudero et al. · JCO Precision Oncology · 2019 · 27 citations

Medicine, Molecular Genetics, Oncology +17